Bit Digital Inc (NASDAQ:BTBT) saw its revenue grew 15% from the prior quarter thanks to the strength of its cloud services.
The company posted total revenue of $32.1 million for the quarter, with cloud services revenue climbing 42% sequentially on new and expanded contracts.
Ideal Power Inc (NASDAQ:IPWR, FRA:5ILA) said it continued to advance commercial development of its B-TRAN bidirectional semiconductor switch technology in the second quarter, including work with a lead Asian customer and an industry partner on prototypes tied to Nvidia's Rubin Ultra 800V DC data center power architecture.
"We continued to execute across our commercial priorities in the second quarter," said David Somo, Ideal Power’s CEO.
Cerebras Systems Inc (NASDAQ:CBRS) shares fell 11% Thursday after the AI chipmaker reported second-quarter revenue below Wall Street estimates, even as the company raised its full-year guidance.
The company posted second-quarter revenue of $180.1 million, missing the $194 million analyst estimate, though up 74% year-over-year.
First Phosphate Corp. (CSE:PHOS, OTCQX:FRSPF, FRA:KD0, OTC:FPHOY, NASDAQ:PHOS) announced that it will ring the Nasdaq Opening Bell on Thursday to mark the company’s recent listing on the Nasdaq Global Market.
The company said its board and management team will attend the ceremony at the Nasdaq Market Site in Times Square, New York, on August 13.
Cisco Systems Inc (NASDAQ:CSCO, XETRA:CIS) reported fiscal fourth-quarter revenue of $17.3 billion, up 18% year-over-year and above the $16.82 billion analyst estimate, as networking demand and artificial intelligence orders drove growth.
Non-GAAP earnings per share came in at $1.22, up 23% year-over-year and ahead of the $1.17 estimate.
Gunnison Copper Corp (TSX:GCU, OTCQB:GCUMF, FRA:3XS0) swung to profitability and posted a sharp jump in revenue in the second quarter, as its Johnson Camp operation moved from ramp-up into active production.
The mining company reported net income of US$13.1 million, or US$0.03 per share, for the second quarter of 2026, as revenue climbed to US$23.6 million on the ramp-up of its Johnson Camp operation.
Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026.
The company said it received FDA “Study May Proceed” authorization for its registrational SkinJect study in patients with Gorlin Syndrome.
374Water Inc (NASDAQ:SCWO, FRA:8LL) announced on Thursday that the US Department of Defense’s Defense Innovation Unit has issued a Success Memo to its demonstration partner Arcadis, validating the performance of 374Water’s AirSCWO technology for PFAS destruction and opening a pathway toward commercial-scale federal procurement.
The memo follows a demonstration and evaluation program conducted under the DoD’s Environmental Security Technology Certification Program.
Shares in Arecor Therapeutics PLC (AIM:AREC) rose 7% to 63.6p after it published full clinical results showing its experimental ultra-concentrated insulin works just as quickly in heavier patients as in lighter ones, a longstanding weak point for high-strength formulations.
The findings appeared in Diabetes, Obesity & Metabolism, marking the first time the complete data from the AT278-104 trial has been peer-reviewed.